AKL-T01 2.2 icon
AKL-T01 2.2

Akili Interactive Labs

App Store

Report updated Apr 24, 2026

Overview · Full Intel report in progress

Play Store →

AKL-T01 2.2 is an established medical app that is completely free.

What is AKL-T01 2.2?

AKL-T01 2.2 is an investigational digital therapeutic intervention developed by Akili Interactive Labs, Inc. for use on mobile iOS devices. The platform utilizes a consumer-grade action videogame interface to deliver simultaneous cognitive tasks through high-quality graphics and reward mechanisms.

Current Momentum

v2.2

We've updated how the IFU (instructions for use) are available via the product label.

AI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.

Competition

Rivals identification in progress

7-Day Rank Pulse 🇺🇸

Medical

No ranking data

MedicalGrossing

Rating Pulse 🇺🇸

Gathering signals...

What makes this app unique?

What Does It Look Like?

How Is The App's Momentum Right Now?

Loading...

What Are The Key Features?

Action Videogame PlatformStandard

Delivers therapeutic content through a consumer-grade, immersive gaming interface.

Simultaneous Cognitive TasksStandard

Incorporates adaptive, multi-tasking challenges designed for digital intervention.

Reward MechanismsStandard

Utilizes integrated reward systems to facilitate engagement within the digital therapeutic environment.

How much does it cost?

Free

Who Built It?

Akili Interactive Labs

(3.1K)

Providing FDA-authorized and clinically-designed game-based digital therapeutics to improve attention and focus for individuals with ADHD.

Portfolio

5

Apps

Free 4
Medical100%

Who is Akili Interactive Labs?

Akili Interactive has established a unique moat by bridging the gap between consumer gaming and regulated medical devices, securing the first-ever FDA authorization for a prescription video game. Their strategy leverages a dual-track distribution model: a prescription-based clinical path for pediatric patients and a direct-to-consumer subscription model for adults. This regulatory-first approach creates a significant barrier to entry for traditional app developers while positioning them as a leader in the emerging digital therapeutics (DTx) category.

Who is Akili Interactive Labs for?

  • Adults with ADHD
  • Parents/caregivers of children (8-17) seeking non-pharmacological
  • Clinically-validated cognitive treatments
Steady

Portfolio momentum

Maintained 3 active apps with 2 updates in the last 6 months, focusing development on their flagship adult and pediatric treatments.

Last release · 57d agoActive apps · 3Abandoned · 2

Analysis in progress, available soon

What do users think recently?

Analysis in progress, available soon

Analysis in progress, available soon

What is the competitive landscape for AKL-T01 2.2?

How's The Medical Market?

Market outlook for this category

Available very soon

Strategic analysis coming soon

SWOT, key takeaways & outlook

The outtake for AKL-T01 2.2

Key Takeaways

This is an investigational medical device restricted to clinical use and is not intended for personal or consumer use.

Where Is It Heading?

Trend analysis

Available very soon

Disclosure

Independent intel to help builders create better apps.

AI-powered analysis with editorial review, built from publicly available sources. See methodology.

Marlvel.ai is not affiliated with, endorsed by, or sponsored by AKL-T01 2.2, its developer, the app publisher, Apple, or Google Play. All trademarks, logos, and screenshots referenced remain the property of their respective owners.

Hope this helps & keep building! · Found an error?

What's new in this report

No changes detected yet.

Cite this report

Marlvel.ai. “AKL-T01 2.2 Intelligence Report.” Updated Apr 24, 2026. https://marlvel.ai/intel-report/medical/akl-t01-2-2

Agent Markdown (.md)·

Data licensed under CC-BY-NC 4.0